Magle Chemoswed Holding Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Magle Chemoswed Holding heeft een totaal eigen vermogen van SEK487.2M en een totale schuld van SEK123.6M, wat de schuld-eigenvermogensverhouding op 25.4% brengt. De totale activa en totale passiva bedragen respectievelijk SEK857.2M en SEK370.0M. De EBIT Magle Chemoswed Holding is SEK25.5M waardoor de rentedekking 4.3 is. Het heeft contanten en kortetermijnbeleggingen van SEK7.3M.

Belangrijke informatie

25.4%

Verhouding schuld/eigen vermogen

SEK 123.59m

Schuld

Rente dekkingsratio	4.3x
Contant	SEK 7.26m
Aandelen	SEK 487.19m
Totaal verplichtingen	SEK 370.02m
Totaal activa	SEK 857.20m

Recente financiële gezondheidsupdates

Magle Chemoswed Holding (STO:MAGLE) Has A Pretty Healthy Balance Sheet

Jun 19

Recent updates

Magle Chemoswed Holding's (STO:MAGLE) Earnings Are Weaker Than They Seem

Nov 04

Market Participants Recognise Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Earnings Pushing Shares 37% Higher

Jun 26

Magle Chemoswed Holding (STO:MAGLE) Has A Pretty Healthy Balance Sheet

Jun 19

Magle Chemoswed Holding's (STO:MAGLE) Earnings Are Of Questionable Quality

Apr 26

Earnings Tell The Story For Magle Chemoswed Holding AB (publ) (STO:MAGLE) As Its Stock Soars 28%

Mar 29

Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Price In Tune With Earnings

Oct 05

Should You Be Impressed By Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) ROE?

Jan 22

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( SEK206.2M ) van MAGLE } dekken niet de korte termijn passiva ( SEK213.4M ).

Langlopende schulden: De kortetermijnactiva MAGLE ( SEK206.2M ) overtreffen de langetermijnschulden ( SEK156.6M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 23.9% ) MAGLE wordt als voldoende beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van MAGLE is de afgelopen 5 jaar gestegen van 15% naar 25.4%.

Schuldendekking: De schuld van MAGLE wordt niet goed gedekt door de operationele kasstroom ( 10.6% ).

Rentedekking: De rentebetalingen op de schuld van MAGLE worden goed gedekt door EBIT ( 4.3 x dekking).

Magle Chemoswed Holding Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Magle Chemoswed Holding (STO:MAGLE) Has A Pretty Healthy Balance Sheet

Recent updates

Magle Chemoswed Holding's (STO:MAGLE) Earnings Are Weaker Than They Seem

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Shareholder dilution

Investor sentiment deteriorates as stock falls 18%

Magle Chemoswed Holding AB (publ) (OM:MAGLE) completed the acquisition of Amniotics AB (publ) (OM:AMNI).

New minor risk - Share price stability

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improves as stock rises 16%

Market Participants Recognise Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Earnings Pushing Shares 37% Higher

Magle Chemoswed Holding (STO:MAGLE) Has A Pretty Healthy Balance Sheet

Magle Chemoswed Holding's (STO:MAGLE) Earnings Are Of Questionable Quality

First quarter 2024 earnings released: EPS: kr0.27 (vs kr0.27 in 1Q 2023)

Earnings Tell The Story For Magle Chemoswed Holding AB (publ) (STO:MAGLE) As Its Stock Soars 28%

Magle Chemoswed Holding AB (publ) (OM:MAGLE) made a tender to acquire 99.96% stake in Amniotics AB (publ) (OM:AMNI) from LSCS Invest AB, Deflexum AB, Marcus Larsson and other for SEK 10.9 million.

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Financial data availability

Magle Chemoswed Holding AB (publ) to Report Q4, 2024 Results on Feb 26, 2025

No independent directors

New minor risk - Share price stability

Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) Price In Tune With Earnings

Investor sentiment improves as stock rises 16%

Full year 2022 earnings released: EPS: kr0.87 (vs kr0.39 in FY 2021)

Magle Chemoswed Holding AB 's Proprietary Product Axxo® Woundgel Receives Regulatory Approval in Kuwait

Magle Group's Vascular Embolic Product Embocept® S Receives Regulatory Approval in Argentina

No independent directors

Magle Group Appoints New Chief Marketing and Innovation Officer

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Magle Chemoswed Holding AB Announces the Resignation of Julia Kamber Rouhi from the Board of Directors of Magle Chemoswed Holding

Magle Group Announces First Patients Enrolled in a Post-Market Study of Medical Device SmartPAN®

Magle Chemoswed Holding AB (publ) Announces Post Market Clinical Study for SmartPAN®

Magle Chemoswed Holding AB (publ) to Report Q4, 2022 Results on Feb 16, 2023

Investor sentiment deteriorated over the past week

No independent directors

Full year 2021 earnings released: EPS: kr0.39 (vs kr0.24 in FY 2020)

Magle Chemoswed Holding AB (publ), Annual General Meeting, May 17, 2022

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Magle Chemoswed Holding AB (publ) to Report Fiscal Year 2021 Results on Feb 25, 2022

Full year 2020 earnings released: EPS kr0.24

Should You Be Impressed By Magle Chemoswed Holding AB (publ)'s (STO:MAGLE) ROE?

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

New 90-day high: kr44.60

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Magle Chemoswed Holding AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 20 million.

New 90-day high: kr35.00

New 90-day high: kr34.60

Magle Chemoswed Holding AB (publ) to Report Fiscal Year 2020 Results on Apr 14, 2021

New 90-day high: kr33.50

New 90-day high: kr30.90

Magle Chemoswed Holding AB (Publ) Announces the Appointment of Joel Eklund as New Member of the Board

Magle Chemoswed Holding AB (publ) has completed an IPO in the amount of SEK 50 million.

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven